Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
Medtronic (NYSE: MDT) plans to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) for chronic pain, for approximately $650 million in cash.
The deal would add SPR’s 60-day, FDA-cleared SPRINT PNS System to Medtronic’s neuromodulation portfolio, with closing expected in the first half of Fiscal 2027, subject to regulatory approvals.
Medtronic (MDT) received CE mark for the Stealth AXiS™ surgical system on April 28, 2026, authorizing use across Europe for spine and cranial procedures. The platform integrates planning, navigation, and robotics with LiveAlign™ segmental tracking and AI-driven planning as part of the AiBLE™ ecosystem.
This follows U.S. FDA clearances earlier in 2026 and is positioned to expand access to integrated surgical workflows across diverse European healthcare systems.
Medtronic (NYSE: MDT) reported interim clinical and regulatory milestones for the Affera system and Sphere catheters on April 25, 2026. Key data: 65.5% of VT patients were free from recurrence at six months; FDA granted Breakthrough Device designation for Sphere-9 and approved a U.S. pivotal IDE. Sphere-360 showed 100% lesion durability in left common pulmonary veins subanalysis, has CE Mark (Jan 2026), and a U.S. IDE is enrolling. First patient enrolled in Conquer-AF to study Sphere-9 in repeat AFib ablations.
Medtronic (NYSE:MDT) completed its acquisition of CathWorks on April 20, 2026, valuing the deal at $585 million with potential undisclosed earn-outs. The purchase adds the CathWorks FFRangio® System—an AI-driven, drug-free, wire-free angiography-derived physiologic assessment—commercially available in the U.S., Europe and Japan.
The ALL-RISE randomized trial (1,900+ patients) showed FFRangio is non-inferior to wire-based FFR for one-year MACE, supporting clinical adoption; Medtronic says the deal is immaterial to FY2027 GAAP and adjusted EPS and neutral to accretive thereafter.
Medtronic (NYSE: MDT) will report fourth quarter and full fiscal year 2026 results on Wednesday, June 3, 2026. The company ends its fiscal year on April 24, 2026.
A news release with summary financial information will be issued at 5:45 a.m. Central Time, followed by a video webcast at 6:45 a.m. CT. A replay and transcript will be posted within 24 hours at the investor relations events page. Contacts for media and investor relations are provided.
Medtronic (NYSE: MDT) received FDA clearance for the Stealth AXiS™ surgical system for cranial and ENT procedures on March 27, 2026. The system unifies planning, navigation, robotics and AI-enabled tractography inside the AiBLE™ ecosystem, and was cleared for spine in February.
The platform integrates intraoperative ultrasound via GE HealthCare bkActiv™ and is designed for continuous software innovation and multi-specialty connectivity.
Medtronic (NYSE: MDT) received FDA approval (March 23, 2026) for an expanded indication for the OmniaSecure defibrillation lead to enable placement in the left bundle branch (LBB) area for conduction system pacing (CSP).
The lumenless, 4.7 French lead is approved for adults and adolescent patients ages 12+, showed 100% defibrillation success at implant and a 2.1% OmniaSecure-related major complication rate at three months in the LEADR LBBAP trial, and commercially launched in the U.S. in January 2026.
Medtronic (NYSE:MDT) agreed to acquire Scientia Vascular for $550 million, subject to customary adjustments and potential earn‑outs, to integrate Scientia's guidewires and catheters into Medtronic's neurovascular portfolio.
The deal covers ~310 employees, targets faster access in stroke care, is expected to close in 1H FY27, and is forecast to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter.
MiniMed Group (Nasdaq: MMED) began trading March 6, 2026 on the Nasdaq Global Select Market following an oversubscribed IPO.
The offering was described as the second largest IPO in medtech history and positions MiniMed to operate as a standalone company, while supporting Medtronic (NYSE: MDT)'s capital-focus strategy amid geopolitical market uncertainty.
MiniMed Group (planned Nasdaq: MMED) priced an initial public offering of 28,000,000 shares at $20.00 per share, with expected Nasdaq trading to begin March 6, 2026 and closing of the offering expected March 9, 2026, subject to customary conditions.
MiniMed granted underwriters a 30-day option for up to 4,200,000 additional shares. Upon completion, Medtronic is expected to retain approximately 90.03% ownership (88.70% if the over-allotment is fully exercised). Proceeds will fund general corporate purposes and may repay intercompany debt to Medtronic.